Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Signs $181 Million Deal to Commercialize CAR-T in China with Huadong

publication date: Jan 17, 2023

Shanghai CARsgen formed a $181 million collaboration with Huadong Medicine to commercialize CARsgen’s lead asset, a BCMA CAR T-cell, in mainland China. CT053 (zevorcabtagene autoleucel (zevor-cel)), is an autologous CAR T-cell product for relapsed/refractory multiple myeloma (R/R MM). CARsgen will receive $30 million upfront and up to $151 million in milestones. In October 2022, CARsgen submitted an NDA for CT053 to China’s NMPA. In late 2022, CARsgen reported positive data from a pivotal China Phase I/II trial for CT053. More details....

Stock Symbols: (HK: 2171) (SHZ: 000963)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital